Securities Purchase Agreement



 Exhibit 10.1 
 EXECUTION VERSION 
 SECURITIES PURCHASE AGREEMENT

 This Securities Purchase Agreement (this “Agreement”) is dated as of December 23, 2009, by and
among Cambridge Heart, Inc., a Delaware corporation (the “Company”), and the purchasers identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the
“Purchasers”). 
 WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to
Section 4(2) of the Securities Act (as defined below) and Rule 506 promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities
of the Company as more fully described in this Agreement. 
 NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained
in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agrees as follows: 
 ARTICLE I 
 DEFINITIONS 
 1.1 Definitions. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following
terms have the meanings indicated in this Section 1.1: 
 “Action” shall have the
meaning ascribed to such term in Section 3.1(j). 
 “Affiliate” means any Person
that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person as such terms are used in and construed under Rule 144 under the Securities Act. With respect to a Purchaser, any
investment fund or managed account that is managed on a discretionary basis by the same investment manager as such Purchaser will be deemed to be an Affiliate of such Purchaser. 
 “Business Day” means any day except Saturday, Sunday and any day which is a federal legal holiday or
a day on which banking institutions in the State of Massachusetts are authorized or required by law or other governmental action to close. 
 “Certificate” shall have the meaning ascribed to such term in Section 2.1. 
 “Closing” means the closing of the purchase and sale of the Preferred Stock and Warrants pursuant to Section 2.1. 
 “Closing Date” means the Trading Day not more than three Trading Days after all conditions precedent
to (i) the Purchasers’ obligations to pay the Subscription Amount and (ii) the Company’s obligations to deliver the Preferred Stock and the Warrants (other than conditions to be satisfied at Closing, which are satisfied or waived
at the Closing) have been satisfied or waived, or such later date as the Company and the Majority Purchasers (as hereinafter defined) agree. 
  

 1 








 “Closing Price” means $0.071 (which is the average
of the closing prices of the Common Stock as reported on the OTC Bulletin Board on the 20 consecutive Trading Days ending on the last trading day prior to December 22, 2009). 
 “Common Stock” means the common stock of the Company, par value $0.001 per share, and any other class
of securities into which such securities may hereafter have been reclassified or changed into. 
 “Common Stock Equivalents” means any securities of the Company or a Subsidiary that entitle the holder thereof to acquire Common Stock at any time, including, without limitation, any debt, preferred stock, rights,
options, warrants or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock. 
 “Company Counsel” means Nutter, McClennen & Fish LLP. 
 “Conversion Shares” means the shares of Common Stock issuable upon conversion of the Preferred
Shares. 
 “Disclosure Schedules” means the Disclosure Schedules of the Company delivered
concurrently herewith. 
 “Equitable Exceptions” shall have the meaning ascribed to such
term in Section 3.1(c). 
 “Evaluation Date” shall have the meaning ascribed to such
term in Section 3.1(r). 
 “Exchange Act” means the Securities Exchange Act of 1934,
as amended. 
 “GAAP” shall have the meaning ascribed to such term in
Section 3.1(h). 
 “Indebtedness” shall have the meaning ascribed to
such term in Section 3.1(z). 
 “Intellectual Property Rights” shall have the
meaning ascribed to such term in Section 3.1(o). 
 “Liens” means a lien, charge,
security interest, encumbrance, right of first refusal, preemptive right or other restriction. 
 “Long-Term Warrants” means the Warrants described in Section 2.2(a)(iv), in the form of Exhibit A attached hereto. 
 “Material Adverse Effect” shall have the meaning assigned to such term in Section 3.1(b).

 “Material Permits” shall have the meaning ascribed to such term in
Section 3.1(m). 
 “Per Share Purchase Price” equals $1,000.00. 
 “Person” means an individual or corporation, partnership, trust, incorporated or unincorporated
association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. 
  

 2 








 “Preferred Shares” means
the shares of Series D Preferred Stock, $.001 par value per share issued or issuable to the Purchasers pursuant to this Agreement 
 “Proceeding” means an action, claim, suit, investigation or proceeding (including, without limitation, an investigation or partial proceeding, such as a deposition), whether
commenced or threatened. 
 “Purchaser Party” shall have the meaning ascribed to such
term in Section 4.7. 
 “Required Approvals” shall have the meaning ascribed to such
term in Section 3.1(e). 
 “Rule 144” means Rule 144 promulgated by the SEC pursuant
to the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the SEC having substantially the same effect as such Rule. 
 “SEC” means the United States Securities and Exchange Commission. 
 “SEC Reports” shall have the meaning ascribed to such term in Section 3.1(h). 
 “Securities” means the Preferred Shares, the Warrants, the Conversion Shares and the Warrant Shares.

 “Securities Act” means the Securities Act of 1933, as amended. 
 “Series C-1 Certificate” means a Certificate of Designation of Series C-1 Preferred Stock in the form
attached hereto as Exhibit C. 
 “Series C Share Exchange” means the issuance of
5,000 shares of Series C-1 Convertible Preferred Stock, $.001 par value per share, of the Company having the rights and preferences set forth in the Series C-1 Certificate to the sole holder of shares of the Company’s Series C Convertible
Preferred Stock, $.001 par value per share (the “Series C Convertible Preferred Stock”) in exchange for 5,000 shares of Series C Convertible Preferred Stock. 
 “Short-Term Warrants” means the Warrants described in
Section 2.2(a)(iii), in the form of Exhibit B attached hereto. 
 “Subscription Amount” shall mean, as to each Purchaser, the amount to be paid for the Preferred Stock purchased hereunder as specified adjacent to such Purchaser’s name and next to
the heading “Subscription Amount” on Schedule I attached hereto, in United States Dollars and in immediately available funds. 
 “Subsidiary” means any subsidiary of the Company as defined in Rule 1-02 of Regulation S-X promulgated by the SEC pursuant to the Exchange Act. 
 “Trading Day” means (i) a day on which the Common Stock is traded on a Trading Market, or
(ii) if the Common Stock is not quoted on any Trading Market, a day on which the Common Stock is quoted in the over-the-counter market as reported by the Pink OTC Markets, Inc. (or any similar organization or agency succeeding to its functions
of reporting prices); provided, that in the event that the Common Stock is not listed or quoted as set forth in (i) and (ii) hereof, then Trading Day shall mean a Business Day. 
  

 3 








 “Trading Market” means whichever of the New York
Stock Exchange, NYSE Amex Equities, the NASDAQ National Market, the NASDAQ SmallCap Market or OTC Bulletin Board on which the Common Stock is listed or quoted for trading on the date in question. 
 “Transaction Documents” means this Agreement, the Certificate of Designation, the Warrants and any
other documents or agreements executed in connection with the transactions contemplated hereunder. 
 “Warrants” means the Warrants described in Sections 2.2(a)(iii) and (iv), including the Short-Term Warrants and the Long-Term Warrants. 
 “Warrant Shares” means the shares of Common Stock issuable upon exercise
of the Warrants. 
 ARTICLE II 
 PURCHASE AND SALE 
 2.1 Closing. The Company shall adopt and file
with the Secretary of State of the State of Delaware on or before the Closing, a Certificate of Designation of Series D Preferred Stock in the form attached hereto as Exhibit D (the “Certificate”). On the Closing Date, upon
the terms and subject to the conditions set forth herein, concurrent with the execution and delivery of this Agreement by the parties hereto, the Company agrees to sell, and each Purchaser severally agrees to purchase that number of Preferred Shares
at the Per Share Purchase Price as set forth opposite such Purchaser’s name on Schedule 1 hereto. Subject to the terms and conditions set forth in this Agreement, at the Closing, each Purchaser shall deliver the Subscription Amount to
the Company via wire transfer and the Company shall deliver to each Purchaser their respective Preferred Shares and Warrants as determined pursuant to Section 2.2(a). Upon satisfaction of the conditions set forth in Sections 2.2 and 2.3, the
Closing shall occur at the offices of Company Counsel, or such other location as the parties shall mutually agree. 
 2.2
Deliveries. 
  

	 	a)	On the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser or a duly designated representative thereof the following:


  

	 	(i)	this Agreement duly executed by the Company; 

  

	 	(ii)	a legal opinion of Company Counsel, in the form of Exhibit E attached hereto; 

  

	 	(iii)	a written certificate from an officer of the Company, dated the Closing Date, confirming that the conditions precedent in Section 2.3(b)(i), (ii) and
(iv) have been satisfied; 

  

	 	(iv)	a certificate evidencing a number of Preferred Shares equal to such Purchaser’s Subscription Amount divided by the Per Share Purchase Price, registered in the name
of such Purchaser; 

  

 4 









	 	(v)	a Short-Term Warrant, registered in the name of such Purchaser, pursuant to which such Purchaser shall have the right to purchase a number of shares of Common Stock
equal to 50% of the quotient obtained by dividing (a) the Subscription Amount by (b) the product of 1.15 multiplied by the Closing Price; and 

  

	 	(vi)	a Long-Term Warrant, registered in the name of such Purchaser, pursuant to which such Purchaser shall have the right to purchase a number of shares of Common Stock
equal to 30% of the quotient obtained by dividing (a) the Subscription Amount by (b) the product of 1.15 multiplied by the Closing Price. 

  

	 	b)	On the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following: 

  

	 	(i)	this Agreement duly executed by such Purchaser; and 

  

	 	(ii)	such Purchaser’s Subscription Amount by wire transfer to the account as specified in writing by the Company. 

 2.3 Closing Conditions. 
  

	 	a)	The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met: 

  

	 	(i)	the accuracy in all material respects when made and on the Closing Date of the representations and warranties of the Purchasers contained herein;


  

	 	(ii)	all obligations, covenants and agreements of the Purchasers required to be performed at or prior to the Closing Date shall have been performed;


  

	 	(iii)	the delivery by the Purchasers of the items set forth in Section 2.2(b) of this Agreement; and 

  

	 	(iv)	the Company shall have filed the Series C-1 Certificate with the Secretary of State of the State of Delaware, consummated the Series C Share Exchange and received the
requisite consent of the sole holder of Series C-1 Convertible Preferred Stock of the Company. 

  

	 	b)	The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met: 

  

	 	(i)	the accuracy in all material respects when made and on the Closing Date of the representations and warranties of the Company contained herein; 


 

 5 









	 	(ii)	all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed; 


 

	 	(iii)	the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement; and 

  

	 	(iv)	there shall have been no Material Adverse Effect with respect to the Company since the date hereof. 

 ARTICLE III 
 REPRESENTATIONS AND WARRANTIES 
 3.1 Representations and Warranties of the Company. Except as set forth
under the corresponding section of the Disclosure Schedules, the Company hereby makes the representations and warranties set forth below to each Purchaser. 
 (a) Subsidiaries. The Company has no subsidiaries. 
 (b)
Organization and Qualification. The Company is duly incorporated, validly existing and in good standing under the laws of the State of Delaware, with the requisite power and authority to own and use its properties and assets and to carry on
its business as currently conducted. The Company is not in violation or default of any of the provisions of its certificate of incorporation and bylaws. The Company is duly qualified to conduct business and is in good standing as a foreign
corporation in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, would not have or
reasonably be expected to result in (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or
condition (financial or otherwise) of the Company, or (iii) a material adverse effect on the Company’s ability to perform in any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or
(iii), a “Material Adverse Effect”), and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification. 
 (c) Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and to
consummate the transactions contemplated by each of the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of each of the Transaction Documents by the Company and the consummation by
it of the transactions contemplated thereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, its board of directors or its stockholders in connection

  

 6 








 
therewith other than in connection with the Series C Share Exchange and the Required Approval. Each Transaction Document has been (or upon delivery will have been) duly executed by the Company
and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms except (i) as such enforceability may be limited
by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of
specific performance, injunctive relief or other equitable remedies, and (iii) insofar as indemnification and contribution provisions may be limited by applicable law (collectively, the “Equitable Exceptions”). 
 (d) No Conflicts. The execution, delivery and performance of the Transaction Documents by the Company and the
consummation by the Company of the transactions contemplated hereby and thereby do not and will not: (i) subject to the consummation of the Series C Share Exchange and the receipt of the Required Approval, conflict with or violate any provision
of the Company’s certificate of incorporation or bylaws, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of
the properties or assets of the Company, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a
Company debt or otherwise) or other understanding to which the Company is a party or by which any property or asset of the Company is bound or affected, or (iii) subject to the consummation of the Series C Share Exchange and receipt of the
Required Approval, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company is subject (including federal and state
securities laws and regulations), or by which any property or asset of the Company is bound or affected; except in the case of each of clauses (ii) and (iii), such as would not have or reasonably be expected to result in a Material Adverse
Effect. 
 (e) Filings, Consents and Approvals. The Company is not required to obtain any consent, waiver,
authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the
Company of the Transaction Documents, other than (i) filings required pursuant to Section 4.4(b), (ii) the filing of Form D with the SEC and such filings as are required to be made under applicable state securities laws, and
(iii) the filing of the Series C-1 Certificate with the Secretary of State of the State of Delaware, the consummation of the Series C Share Exchange, and the requisite consent of the sole holder of the Series C Convertible Preferred Stock
(which shall be the sole holder of Series C-1 Convertible Preferred Stock following the Series C Share Exchange) (the “Required Approval”). 
  

 7 








 (f) Issuance of the Securities. The Preferred Shares and Warrants are
duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company other than restrictions on
transfer provided for in the Transaction Documents. The Conversion Shares have been duly authorized and reserved for issuance and when so issued in accordance with the terms of the applicable Transaction Documents, will be validly issued, fully paid
and nonassessable, free and clear of all Liens imposed by the Company. The Warrant Shares have been duly authorized and reserved for issuance upon exercise of the Warrants and when so issued in accordance with the terms of the Warrants will be
validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company other than restrictions on transfer provided for in the Transaction Documents. 
 (g) Capitalization. The capitalization of the Company is as set forth on Schedule 3.1(g) hereto. The Company
has not issued any capital stock since its most recently filed periodic report under the Exchange Act other than pursuant to the exercise of employee stock options under the Company’s stock option plans, the issuance of shares of Common Stock
to employees pursuant to existing employee benefit plans or pursuant to the conversion or exercise of outstanding Common Stock Equivalents. No Person has any right of first refusal, preemptive right, right of participation, or any similar right to
participate in the transactions contemplated by the Transaction Documents. Except (i) as a result of the purchase and sale of the Shares, (ii) as set forth in the Company’s most recently filed periodic report under the Exchange Act,
or (iii) as set forth on Schedule 3.1(g), there are no outstanding options, warrants, rights to subscribe to, calls or commitments of any kind whatsoever relating to, or securities, rights or obligations convertible into or exercisable
or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock, or contracts, commitments, understandings or arrangements by which the Company is or may become bound to issue additional shares of Common
Stock, or Common Stock Equivalents. The issuance and sale of the Securities will not obligate the Company to issue shares of Common Stock or other securities to any Person (other than the Purchasers) and will not result in a right of any holder of
Company securities to adjust the exercise, conversion, exchange or reset price under such securities. All of the outstanding shares of capital stock of the Company are validly issued, fully paid and nonassessable, have been issued in compliance in
all material respects with all federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. Any statements in the SEC Reports (as
defined below) regarding employee and director stock options are accurate in all material respects. There are no stockholders agreements, voting agreements or other similar agreements with respect to the Company’s capital stock to which the
Company is a party or, to the knowledge of the Company, between or among any of the Company’s stockholders. 
 (h) SEC Reports; Financial Statements. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by it under the Securities Act and the Exchange Act, including pursuant to
Section 13(a) or 15(d)

  

 8 








 
thereof, for the two years preceding the date hereof (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred to
herein as the “SEC Reports”) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports
complied in all material respects with the requirements of the Securities Act and the Exchange Act and the rules and regulations of the SEC promulgated thereunder, and none of the SEC Reports, when filed, contained any untrue statement of a material
fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The financial statements of the Company included
in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance
with United States generally accepted accounting principles (“GAAP”) applied on a consistent basis during the periods involved, except as may be otherwise specified in such financial statements or the notes thereto and except that
unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company as of and for the dates thereof and the results of operations and cash flows for the
periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments. 
 (i) Material Changes. Since the date of the latest audited financial statements included within the SEC Reports, except as specifically disclosed in the SEC Reports, (i) there has been no event, occurrence or development that
has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary
course of business consistent with past practice and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to GAAP or required to be disclosed in filings made with the SEC, (iii) the Company has
not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its
capital stock except as disclosed on Schedule 3.1(i), and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock option or stock plans. The Company does not
have pending before the SEC any request for confidential treatment of information, except as disclosed on Schedule 3.1(i). 
 (j) Litigation. There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened in writing against or affecting the
Company or any of its properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an “Action”) which (i) adversely
affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii) could, if there were an unfavorable decision, individually or in the aggregate, have

  

 9 








 
or reasonably be expected to result in a Material Adverse Effect. No director or officer of the Company, is or has been the subject of any Action involving a claim of violation of or liability
under federal or state securities laws or a claim of breach of fiduciary duty within the last five years. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the SEC involving the
Company or to the knowledge of the Company any current or former director or officer of the Company. The SEC has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any
Subsidiary under the Exchange Act or the Securities Act. 
 (k) Labor Relations. No material labor dispute
exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company which could reasonably be expected to result in a Material Adverse Effect. 
 (l) Compliance. The Company (i) neither is in default under or in violation of (and no event has occurred that
has not been waived that, with notice or lapse of time or both, would result in a default by the Company under), nor has the Company received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit
agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is not in violation of any order of any court, arbitrator or
governmental body, and (iii) neither is nor has been in violation of any statute, rule or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws applicable to its business except in
each case as could not reasonably be expected to have a Material Adverse Effect. 
 (m) Regulatory
Permits. The Company possesses all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct its business as described in the SEC Reports, except where the
failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (“Material Permits”), and neither the Company nor any Subsidiary has not received any notice of proceedings relating to the
revocation or modification of any Material Permit. 
 (n) Title to Assets. The Company owns no real
property and has good title in all personal property owned by it that is material to the business of the Company, in each case free and clear of all Liens, except for Liens as do not materially affect the value of such property and do not materially
interfere with the use made and proposed to be made of such property by the Company and Liens for the payment of federal, state or other taxes, the payment of which is neither delinquent nor subject to penalties. Any real property and facilities
held under lease by the Company are held by it under valid, subsisting and enforceable leases of which the Company is in compliance, except as could not reasonably be expected to result in a Material Adverse Effect. 
  

 10 








 (o) Patents and Trademarks. The Company has, or has rights to use,
all patents, patent applications, trademarks, trademark applications, service marks, trade names, copyrights, licenses and other similar rights that are necessary or material for use in connection with its business as described in the SEC Reports,
except for such instances, if any, where the failure to have such rights could not reasonably be expected to have a Material Adverse Effect (collectively, the “Intellectual Property Rights”). The Company has not (i) received a
written notice that the Intellectual Property Rights used by the Company violate or infringe upon the rights of any Person, or (ii) received a written invitation to license any Intellectual Property Rights of a Person in order to avoid such a
violation or infringement. To the knowledge of the Company, all such Intellectual Property Rights are enforceable (subject only to the Equitable Exceptions) and there is no existing infringement by another Person of any of the Intellectual Property
Rights. 
 (p) Insurance. The Company is insured by insurers of recognized financial responsibility
against such losses and risks, including, without limitation, products liability, and in such amounts as are prudent and customary in the businesses in which the Company is engaged, including, but not limited to, directors and officers insurance
coverage at least equal to the aggregate Subscription Amount. To the best knowledge of the Company, such insurance contracts and policies are accurate and complete. The Company has no reason to believe that it will not be able to renew its existing
insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business on terms consistent with market for the Company’s line of business. 
 (q) Transactions With Affiliates and Employees. Except as set forth in the SEC Reports, none of the officers or
directors of the Company, or any person who served as an officer or director in the 12 months prior to the date of this Agreement, and, to the knowledge of the Company, none of the employees of the Company is presently a party to any transaction
with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal
property to or from, or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer,
director, trustee or partner, in each case in excess of $120,000 other than (i) for payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) for other
equity compensation or employee benefits, including, without limitation, stock option agreements under any stock option plan of the Company. 
 (r) Sarbanes-Oxley; Internal Accounting Controls. The Company is in material compliance with all provisions of the Sarbanes-Oxley Act of 2002 which are applicable to it as of the Closing Date. The
Company maintains a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions are

  

 11 








 
recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with
management’s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company has
established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and designed such disclosure controls and procedures to ensure that material information relating to the Company, including its
Subsidiaries, is made known to the certifying officers by others within those entities, particularly during the period in which the Company’s most recently filed periodic report under the Exchange Act, as the case may be, is being prepared. The
Company’s certifying officers have evaluated the effectiveness of the Company’s controls and procedures as of the date prior to the filing date of the most recently filed periodic report under the Exchange Act (such date, the
“Evaluation Date”). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their
evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no significant changes in the Company’s internal controls (as such term is defined in Item 307(b) of Regulation S-K under the Exchange Act) or, to the
knowledge of the Company, in other factors that could significantly affect the Company’s internal controls. 
 (s) Certain Fees. No brokerage or finder’s fees or commissions are or will be payable by the Company to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect
to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that
may be due in connection with the transactions contemplated by the Transaction Documents. 
 (t) Private
Placement. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3.2, no registration under the Securities Act is required for the offer and sale of the Securities by the Company to the Purchasers
as contemplated hereby. The issuance and sale of the Securities hereunder does not contravene the rules and regulations of the Trading Market. 
 (u) Investment Company. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Shares, will not be an Affiliate of, an “investment company”
within the meaning of the Investment Company Act of 1940, as amended. 
 (v) Listing and Maintenance
Requirements. The Company’s Common Stock is registered pursuant to Section 12(g) of the Exchange Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the
registration of the Common Stock under the Exchange Act, nor has the Company received any notification that the SEC is contemplating terminating such registration. 
  

 12 








 (w) Application of Takeover Protections. The Company and its Board of
Directors have taken all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision under
the Company’s Certificate of Incorporation (or similar charter documents) or the laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their obligations
or exercising their rights under the Transaction Documents, including without limitation as a result of the Company’s issuance of the Securities and the Purchasers’ ownership of the Securities. 
 (x) Disclosure. All disclosure provided to the Purchasers regarding the Company, its business and the transactions
contemplated hereby, including the Disclosure Schedules to this Agreement, furnished by or on behalf of the Company with respect to the representation and warranties made herein are true and correct with respect to such representations and
warranties and do not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. 
 (y) No Integrated Offering. Assuming the accuracy of the Purchasers’ representations and warranties set forth in
Section 3.2, neither the Company, nor, to the knowledge of the Company, any Affiliate of the Company or any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to
buy any security, under circumstances that would cause this offering of the Securities to be integrated with prior offerings by the Company for purposes of the Securities Act or any applicable stockholder approval provisions, including, without
limitation, under the rules and regulations of any Trading Market on which any of the securities of the Company are listed or designated. 
 (z) Solvency. Based on the financial condition of the Company as of the Closing Date after giving effect to the receipt by the Company of the proceeds from the sale of the Securities hereunder,
(i) the Company’s fair saleable value of its assets exceeds the amount that will be required to be paid on or in respect of the Company’s existing debts and other liabilities (including known contingent liabilities) as they mature;
(ii) the Company’s assets do not constitute unreasonably small capital to carry on its business for the current fiscal year as now conducted and as proposed to be conducted including its capital needs taking into account the particular
capital requirements of the business conducted by the Company, and projected capital requirements and capital availability thereof; and (iii) the current cash flow of the Company, together with the proceeds the Company would receive, were it to
liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its debt when such amounts are required to be paid. The Company does not intend to incur debts beyond
its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of any facts or circumstances which lead it to believe that it will file for

  

 13 








 
reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date. The SEC Reports set forth as of the dates thereof all
outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, “Indebtedness” shall mean (a) any liabilities for
borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary course of business), (b) all guaranties, endorsements and other contingent obligations in respect of Indebtedness of others, whether
or not the same are or should be reflected in the Company’s balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business;
and (c) the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance with GAAP. The Company is not in default with respect to any Indebtedness. 
 (aa) Tax Status. Except for matters that would not, individually or in the aggregate, have or reasonably be expected
to result in a Material Adverse Effect, the Company (i) has filed all necessary federal, state and foreign income and franchise tax returns and has paid or accrued all taxes shown as due thereon, and (ii) has no knowledge of a tax
deficiency which has been asserted or threatened against the Company. 
 (bb) No General Solicitation.
Neither the Company nor any Person acting on behalf of the Company has offered or sold any of the Securities by any form of general solicitation or general advertising. The Company has offered the Securities for sale only to the Purchasers and
certain other “accredited investors” within the meaning of Rule 501 under the Securities Act. 
 (cc)
Foreign Corrupt Practices. Neither the Company, nor to the knowledge of the Company, any agent or other person acting on behalf of the Company, has (i) directly or indirectly, used any funds for unlawful contributions, gifts,
entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns
from corporate funds, (iii) failed to disclose fully any contribution made by the Company (or made by any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any
provision of the Foreign Corrupt Practices Act of 1977, as amended 
 (dd) Accountants. The Company’s
accountants are set forth in the SEC Reports. To the Company’s knowledge, such accountants, who the Company expects will express their opinion with respect to the financial statements to be included in the Company’s Annual Report on Form
10-K for the year ending December 31, 2009, are a registered public accounting firm as required by the Securities Act. 
 (ee) Acknowledgment Regarding Purchasers’ Purchase of Securities. The Company acknowledges and agrees that each of the Purchasers is acting solely in the capacity of an arm’s length
purchaser with respect to the Transaction Documents and the transactions

  

 14 








 
contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to this Agreement
and the transactions contemplated hereby and any advice given by any Purchaser or any of their respective representatives or agents in connection with this Agreement and the transactions contemplated hereby is merely incidental to the
Purchasers’ purchase of the Securities. The Company further represents to each Purchaser that the Company’s decision to enter into this Agreement has been based solely on the independent evaluation of the transactions contemplated hereby
by the Company and its representatives. 
 (ff) Manipulation of Price. The Company has not, and to
its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any
of the Shares, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the Shares (other than for the placement agent’s placement of the Shares), or (iii) paid or agreed to pay to any person any
compensation for soliciting another to purchase any other Shares of the Company. 
 (gg) FDA Compliance.
The conduct of business by the Company complies, and at all times has substantially complied, in all material respects with (a) the Federal Food, Drug and Cosmetic Act and similar federal, state, local and foreign laws applicable to the
evaluation, testing, manufacturing, distribution, advertising and marketing of each of the Company’s products, in whatever stage of development or commercialization, and (b) the Federal Anti-Kickback Statute and any similar health care
fraud and abuse laws. The Company has not received any notification asserting, or has no knowledge of, any present or past failure to comply with or violation of any such act and statutes. 
 (ii) No False Statements. Neither the Company nor any officer, employee or agent of the Company has made an untrue
statement of a material fact or fraudulent statement to the FDA or any other governmental entity, failed to disclose a material fact required to be disclosed to the FDA or any other governmental entity, or committed an act, made a statement, or
failed to make a statement that, at the time such disclosure was made, in each case, relating to Company’s business, could reasonably be expected to provide a basis for the FDA or any other governmental entity to invoke any policies respecting
Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities, including but not limited to the FDA policy set forth in 56 Fed. Reg. 46191 (September 10, 1991) or any similar policy. The Company has not been convicted of any crime or
engaged in any conduct for which debarment is mandated by 21 U.S.C. § 335a(a) or any similar law for which debarment is authorized by 21 U.S.C. § 335a(b) or any similar law. 
 (jj) Disclaimer of Other Representations and Warranties; Knowledge. 
 (i) The Company does not make and has not made, and shall not be deemed to have made, any representations or warranties
relating to the Company’s business or assets, or otherwise in connection with the transactions contemplated hereby, other

  

 15 








 
than those expressly set forth herein which are made by the Company. Without limiting the generality of the foregoing, the Company has not made and shall not be deemed to have made, any
representations or warranties as to the information contained in any presentation relating to the Company in connection with the transactions contemplated hereby, and no statement made in any such presentation shall be deemed a representation or
warranty hereunder or otherwise. It is understood that any cost estimates, projections or other predictions, any data, and any financial information or presentations by the Company’s management are not and shall not be deemed to be or to
include representations or warranties of Company (it being understood that this Section 3.1(jj) shall not be deemed to limit the representations and warranties contained herein, including, without limitation, those with respect to the SEC
Reports). No person has been authorized by the Company to make any representation or warranty relating to the Company or otherwise in connection with the transactions contemplated hereby and, if made, such representation or warranty must not be
relied upon as having been authorized by the Company. 
 (ii) Whenever a representation or warranty made by the
Company herein refers to the knowledge of the Company, such knowledge shall be deemed to consist only of the actual knowledge of the officers of the Company. 
 3.2 Representations and Warranties of the Purchasers. Each Purchaser hereby, for itself and for no other Purchaser, represents and warrants as of the date hereof and as of the Closing Date to the
Company as follows: 
 (a) Organization; Authority. Such Purchaser has full power and authority to enter
into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry out the obligations thereunder. Each Purchaser not a natural person is duly organized, validly existing and in good standing under the laws of
the jurisdiction of its organization with full right, corporate or partnership power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry out its obligations thereunder. The
execution, delivery and performance by each Purchaser that is not a natural person of the transactions contemplated by this Agreement have been duly authorized by all necessary corporate or similar action on the part of such Purchaser. 

(b) Execution. Each Transaction Document to which such Purchaser is a party has been duly executed by such
Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except (i) as limited by
general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability
of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law. 
  

 16 








 (c) Own Account. Such Purchaser understands that the Securities are
restricted securities and have not been registered under the Securities Act or any applicable state securities law and is acquiring the Securities as principal for its own account and not with a view to or for distributing or reselling such
Securities or any part thereof in violation of the Securities Act or any applicable state securities law, has no present intention of distributing any of such Securities in violation of the Securities Act or any applicable state securities law and
has no arrangement or understanding with any other persons regarding the distribution of such Securities (this representation and warranty not limiting such Purchaser’s right to sell the Securities in compliance with applicable federal and
state securities laws) in violation of the Securities Act or any applicable state securities law. The Purchaser does not have any agreement or understanding, directly or indirectly, with any Person to distribute any of the Securities. 
 (d) Purchaser Status. At the time such Purchaser was offered the Securities, it was, and at the date hereof it is, and
on each date on which it converts the Preferred Shares into Conversion Shares or exercises any Warrants, it will be either: (i) an “accredited investor” as defined in Rule 501(a) under the Securities Act or (ii) a “qualified
institutional buyer” as defined in Rule 144A(a) under the Securities Act. Such Purchaser is not required to be registered as a broker-dealer under Section 15 of the Exchange Act. 
 (e) Experience of Such Purchaser. Such Purchaser, either alone or together with its representatives, has such
knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has so evaluated the merits and risks of such investment. Such
Purchaser is able to bear the economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment. 
 (f) General Solicitation. Such Purchaser is not purchasing the Securities as a result of any advertisement, article,
notice or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or any other general solicitation or general advertisement. 
 (g) Access to Information. Such Purchaser acknowledges that it has reviewed the Disclosure Schedules and has been
afforded (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities and the merits and risks of
investing in the Securities; (ii) access to information about the Company and its financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the
opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment. Neither such inquiries nor
any other investigation conducted by or on behalf of such Purchaser or its representatives or counsel shall modify, amend or affect

  

 17 








 
the Purchaser’s right to rely on the truth, accuracy and completeness of the Disclosure Schedules and the Company’s representations and warranties contained in the Transaction
Documents. 
 (h) Disclosure. Such Purchaser acknowledges and agrees that the Company does not make and
has not made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.1 hereof. 
 (i) Address. Such Purchaser’s address on the signature page hereto indicates the true state of residence of such
Purchaser. 
 (j) Transactions in Securities. During the period from the commencement of negotiations
between such Purchaser and the Company with respect to the transactions contemplated by this Agreement and the date hereof, such Purchaser has not established a short position with respect to the Company’s Common Stock. 
 ARTICLE IV 
 OTHER AGREEMENTS OF THE PARTIES 
 4.1 Transfer Restrictions. 
 (a) The Securities may only be disposed of in compliance with state and federal securities laws. In connection with any
transfer of Securities other than pursuant to an effective registration statement or Rule 144, to the Company or to an Affiliate of a Purchaser or in connection with a pledge as contemplated in Section 4.1(b), the Company may require the
transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such
transfer does not require registration of such transferred Securities under the Securities Act. 
 (b) The
Purchasers agree to the imprinting, so long as is required by this Section 4.1(b), of a legend on any of the Securities in the following form: 
 [NEITHER] THESE SECURITIES [NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE [EXERCISABLE] [CONVERTIBLE]] HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF
ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE
SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH

  

 18 








 
APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THESE
SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN “ACCREDITED
INVESTOR” AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT. 
 The Company acknowledges and agrees that a
Purchaser may from time to time pledge or grant a security interest in some or all of the Securities to a financial institution that is an “accredited investor” as defined in Rule 501(a) under the Securities Act and who agrees to be bound
by the provisions of this Agreement and, if required under the terms of such arrangement, such Purchaser may transfer pledged or secured Securities to the pledgees or secured parties. Such a pledge or transfer would not be subject to approval of the
Company and no legal opinion of legal counsel of the pledgee, secured party or pledgor shall be required in connection therewith. Further, no notice shall be required of such pledge. At the appropriate Purchaser’s expense, the Company will
execute and deliver such reasonable documentation as a pledgee or secured party of Securities may reasonably request in connection with a pledge or transfer of the Securities. 
 (c) Certificates evidencing the Conversion Shares and Warrant Shares shall not contain any legend (including the legend set
forth in Section 4.1(b) hereof): (i) following any sale of such Conversion Shares or Warrant Shares pursuant to Rule 144 (assuming the transferor is not an Affiliate of the Company) or (ii) if such legend is not required under
applicable requirements of the Securities Act and the rules and regulations promulgated thereunder (including judicial interpretations and pronouncements issued by the staff of the SEC). The Company agrees that at such time as such legend is no
longer required under this Section 4.1(c), it will, no later than three Trading Days following the delivery by a Purchaser to the Company or the Company’s transfer agent of a certificate representing Conversion Shares or Warrant Shares, as
applicable, issued with a restrictive legend, and receipt by the Company and Company Counsel of a written request that the Company remove the legend from such certificate, deliver or cause to be delivered to such Purchaser a certificate representing
such shares that is free from all restrictive and other legends. The Company may not make any notation on its records or give instructions to any transfer agent of the Company that enlarge the restrictions on transfer set forth in this Section.
Certificates for Conversion Shares or Warrant Shares subject to legend removal hereunder shall be transmitted by the transfer agent of the Company to the Purchasers by crediting the account of the Purchaser’s prime broker with the Depository
Trust Company’s Direct Registration System. 
 4.2 Furnishing of Information. As long as any Purchaser owns
Securities, the Company covenants to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to

  

 19 








 
the Exchange Act. As long as any Purchaser owns Securities, if the Company is not required to file reports pursuant to the Exchange Act, it will prepare and furnish to the Purchasers and make
publicly available in accordance with Rule 144(c) such information as is required for the Purchasers to sell the Securities under Rule 144. The Company further covenants that it will take such further action as any holder of Securities may
reasonably request, all to the extent required from time to time to enable such Purchaser to sell such Securities without registration under the Securities Act within the limitation of the exemptions provided by Rule 144. 
 4.3 Integration. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any
security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would require the registration under the Securities Act of the sale of the Securities to the Purchasers
or that would be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any Trading Market such that it would require stockholder approval of the sale of Securities to the Purchasers unless stockholder
approval is obtained before the closing of such subsequent transactions. 
 4.4 Confidentiality; Required Disclosure.

 (a) Each party agrees, and will cause its affiliates, to keep confidential and not to publish (by press release, press
interview, or otherwise) or otherwise divulge or use for its own benefit or for the benefit of any third party any information of a confidential or proprietary nature furnished to it by the other party, or the existence and terms of this Agreement,
without the prior written approval of the other party, except to those of such party’s employees and representatives as may need to know such information for purposes of the transactions contemplated by the parties’ agreements, and except
as required by applicable law or by obligations pursuant to any listing agreement with or rules of any Trading Market. In the event of any such required disclosure, including the filings described in Section 4.4(b) below, the disclosing party
will (i) provide the other party with written notice of the required disclosure at least 48 hours in advance of such disclosure, and (ii) limit such disclosure to the minimum required under the applicable law or obligations, whether
through a request for confidential treatment or otherwise. The confidentiality obligation described above shall not apply to information of the other party which: (a) was already known by the recipient prior to the time of its disclosure by the
disclosing party to the recipient; (b) is publicly available or later becomes publicly available through no fault of the recipient; or (c) is disclosed to the recipient by a third party having no similar confidentiality obligation. This
obligation shall terminate three years after execution of this Agreement. 
 (b) The Company shall (i) timely file with the
SEC a Current Report on Form 8-K with respect to the transactions contemplated by this Agreement, and (ii) make such other filings and notices in the manner and time required by the SEC and the Trading Market, provided, in the case of a filing
or notice described in clause (i) or (ii) above, that the information contained in such filing or notice is limited to the information necessary in order for the Company to comply with the Exchange Act and the regulations promulgated
thereunder or the other applicable legal or Trading Market obligations. 
  

 20 








 4.5 Stockholder Rights Plan. No claim will be made or enforced by the Company or, to
the knowledge of the Company, any other Person that any Purchaser is an “Acquiring Person” under any stockholder rights plan or similar plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser could be
deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents. The Company shall conduct its business in a manner so that it will not become subject to the Investment Company Act.

 4.6 Use of Proceeds. The Company shall use the net proceeds from the sale of the Securities hereunder for working
capital purposes and not for the satisfaction of any portion of the Company’s debt (other than payment of trade payables in the ordinary course of the Company’s business and prior practices), to redeem any Company equity or
equity-equivalent securities or to settle any outstanding litigation. 
 4.7 Indemnification of Purchasers. Subject to
the provisions of this Section 4.7, the Company will indemnify and hold the Purchasers and their respective directors, officers, shareholders, partners, employees and agents (each, a “Purchaser Party”) harmless from any and all
losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys’ fees and costs of investigation that any such Purchaser Party may
suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents or (b) any action instituted
against a Purchaser, or any of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser, with respect to any of the transactions contemplated by the Transaction Documents (unless such action is
based upon a breach of such Purchaser’s representation, warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser may have with any such stockholder or any violations by the Purchaser of state or
federal securities laws or any conduct by such Purchaser which constitutes fraud, gross negligence, willful misconduct or malfeasance). If any action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant
to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing. Any Purchaser Party shall have the right to employ separate
counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that (i) the employment thereof has been specifically authorized
by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of such separate counsel, a material conflict
on any material issue between the position of the Company and the position of such Purchaser Party. The Company will not be liable to any Purchaser Party under this Agreement (i) for any settlement by a Purchaser Party effected without the
Company’s prior written consent, which shall not be unreasonably withheld or delayed; or (ii) to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party’s breach of any of the
representations, warranties, covenants or agreements made by the Purchasers in this Agreement or in the other Transaction Documents. 
  

 21 








 4.8 Reservation of Common Stock. The Company shall maintain a reserve, free of
preemptive rights, from its duly authorized shares of Common Stock for issuance pursuant to the Transaction Documents in such amount as may be required to fulfill its obligations under the Transaction Documents in full, including the issuance of
Conversion Shares and Warrant Shares. 
 ARTICLE V 
 MISCELLANEOUS 
 5.1 Termination. This Agreement
may be terminated by Purchasers who would constitute a majority of the holders of Preferred Stock at Closing (“Majority Purchasers”), by written notice to the other parties, if the Closing has not been consummated on or before
January 31, 2010. 
 5.2 Fees and Expenses. Except as expressly set forth in the Transaction Documents to the
contrary, each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this
Agreement. The Company shall pay all transfer agent fees, stamp taxes and other taxes and duties levied in connection with the delivery of any Securities. 
 5.3 Entire Agreement. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of the parties with respect to the subject matter hereof and
supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules. 
 5.4 Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in
writing and shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number set forth on the signature pages attached hereto prior to 5:30
p.m. (Eastern Time) on a Trading Day, (b) the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number set forth on the signature pages attached hereto on a day that is
not a Trading Day or later than 5:30 p.m. (Eastern Time) on any Trading Day, (c) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (d) upon actual receipt by the party
to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto until changed by notice given in accordance with this Section. 
  

 22 








 5.5 Amendments; Waivers. No provision of this Agreement may be waived or amended
except in a written instrument signed, in the case of an amendment, by the Company and the Majority Purchasers or, in the case of a waiver, by the party against whom enforcement of any such waiver is sought. No waiver of any default with respect to
any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or
omission of either party to exercise any right hereunder in any manner impair the exercise of any such right. 
 5.6
Headings. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof. The language used in this Agreement will be deemed to be the language
chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party. 
 5.7 Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder
without the prior written consent of each Purchaser. Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or transfers any Securities, provided such transferee agrees in writing to be
bound, with respect to the transferred Securities, by the provisions hereof that apply to the “Purchasers”. 
 5.8
No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person,
except as otherwise set forth in Section 4.7. 
 5.9 Governing Law. All questions concerning the construction,
validity, enforcement and interpretation of the Transaction Documents shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof, except
to the extent that the application of the General Corporation Law of the State of Delaware is mandatorily applicable. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates, directors, officers, stockholders, employees or agents) shall be commenced exclusively in the state and federal
courts located in Middlesex County, Massachusetts, USA. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts located in Middlesex County, Massachusetts, USA, for the adjudication of any dispute
hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any suit,
action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, or that such suit, action or proceeding has been commenced in an improper or inconvenient venue for such proceeding. Each party hereby
irrevocably waives personal

  

 23 








 
service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of
delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any
way any right to serve process in any manner permitted by law. Each party hereto hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to
this Agreement or the transactions contemplated hereby. If any party shall commence an action or proceeding to enforce any provisions of the Transaction Documents, then the prevailing party in such action or proceeding shall be reimbursed by the
other party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding. 
 5.10 Survival. The representations, warranties, agreements and covenants contained herein shall survive the Closing and the delivery,
conversion and/or exercise of the Securities, as applicable, for the applicable statute of limitations. 
 5.11
Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered
to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission, such signature shall create a valid and binding obligation of the party executing
(or on whose behalf such signature is executed) with the same force and effect as if such facsimile signature page were an original thereof. 
 5.12 Severability. If any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Agreement
shall not in any way be affected or impaired thereby and the parties will attempt to agree upon a valid and enforceable provision that is a reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this
Agreement. 
 5.14 Replacement of Securities. If any certificate or instrument evidencing any of the Securities is
mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof, or in lieu of and substitution therefore, a new certificate or instrument, but only upon receipt of
evidence reasonably satisfactory to the Company of such loss, theft or destruction and customary and reasonable indemnity, if requested. The applicants for a new certificate or instrument under such circumstances shall also pay any reasonable
third-party costs associated with the issuance of such replacement Securities. If a replacement certificate or instrument evidencing Securities is requested due to a mutilation thereof, the Company may require delivery of such mutilated certificate
or instrument as a condition precedent to any issuance of a replacement Security. 
 5.15 Remedies. In addition to being
entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers and the Company will

  

 24 








 
be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of
obligations described in the foregoing sentence and hereby agrees to waive in any action for specific performance of any such obligation the defense that a remedy at law would be adequate. 
 5.16 Independent Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under any Transaction Document
are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any
Transaction Document, and no action taken by any Purchaser pursuant thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are
in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Document. Each Purchaser shall be entitled to independently protect and enforce its rights, including, without
limitation, the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any proceeding for such purpose. Each Purchaser has been
represented by its own separate legal counsel in their review and negotiation of the Transaction Documents. 
 [SIGNATURE PAGE
FOLLOWS] 
  

 25 








 IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be
duly executed by their respective authorized signatories as of the date first indicated above. 
  

							
	CAMBRIDGE HEART, INC.	 		 	Address for Notice:
				
	By:	 	 /s/ Ali Haghighi-Mood
	 		 	100 Ames Pond Drive
	Name:	 	Ali Haghighi-Mood	 		 	Tewksbury, MA 01876
	Title:	 	President and Chief Executive Officer	 		 	Attn: President
			
	With a copy to (which shall not constitute notice):	 		 	 Nutter, McClennen & Fish LLP
 155 Seaport Blvd.
 Boston, MA 02210
 Attn: Michelle L. Basil, Esq.


 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK 
 SIGNATURE PAGE FOR PURCHASER FOLLOWS] 
  

 26 








 [PURCHASER SIGNATURE PAGES TO CAMBRIDGE HEART SECURITIES 
 PURCHASE AGREEMENT] 
 IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. 
  

			
	Name of Investing Entity or Person:	  	 Cyril Malak

		
	Signature of Authorized Signatory of Investing Entity or Person:	  	  

		
	Name of Authorized Signatory:	  	  

		
	Title of Authorized Signatory:	  	  

		
	Email Address of Authorized Signatory:	  	  

		
	Address for Notice of Investing Entity or Person:	  	
		
	  
	  	
		
	  
	  	
		
	  
	  	
	
	Address for Delivery of Securities for Investing Entity or Person (if not same as above):
		
	  
	  	
		
	  
	  	
		
	  
	  	

 EIN Number: [PROVIDE THIS UNDER SEPARATE COVER]  
 [SIGNATURE PAGES CONTINUE] 
  

 27 








 [PURCHASER SIGNATURE PAGES TO CAMBRIDGE HEART SECURITIES 
 PURCHASE AGREEMENT] 
 IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. 
  

			
	Name of Investing Entity or Person:	  	 John Hynes

		
	Signature of Authorized Signatory of Investing Entity or Person:	  	  

		
	Name of Authorized Signatory:	  	  

		
	Title of Authorized Signatory:	  	  

		
	Email Address of Authorized Signatory:	  	  

		
	Address for Notice of Investing Entity or Person:	  	
		
	  
	  	
		
	  
	  	
		
	  
	  	
	
	Address for Delivery of Securities for Investing Entity or Person (if not same as above):
		
	  
	  	
		
	  
	  	
		
	  
	  	

 EIN Number: [PROVIDE THIS UNDER SEPARATE COVER]  
  
 [SIGNATURE PAGES CONTINUE] 
  

 28 








 [PURCHASER SIGNATURE PAGES TO CAMBRIDGE HEART SECURITIES 
 PURCHASE AGREEMENT] 
 IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. 
  

			
	Name of Investing Entity or Person:	  	 Vicente Madrigal

		
	Signature of Authorized Signatory of Investing Entity or Person:	  	  

		
	Name of Authorized Signatory:	  	  

		
	Title of Authorized Signatory:	  	  

		
	Email Address of Authorized Signatory:	  	  

		
	Address for Notice of Investing Entity or Person:	  	
		
	  
	  	
		
	  
	  	
		
	  
	  	
	
	Address for Delivery of Securities for Investing Entity or Person (if not same as above):
		
	  
	  	
		
	  
	  	
		
	  
	  	

 EIN Number: [PROVIDE THIS UNDER SEPARATE COVER]  
  
 [SIGNATURE PAGES CONTINUE] 
  

 29 








 [PURCHASER SIGNATURE PAGES TO CAMBRIDGE HEART SECURITIES 
 PURCHASE AGREEMENT] 
 IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. 
  

			
	Name of Investing Entity or Person:	  	 Gerardo Madrigal

		
	Signature of Authorized Signatory of Investing Entity or Person:	  	  

		
	Name of Authorized Signatory:	  	  

		
	Title of Authorized Signatory:	  	  

		
	Email Address of Authorized Signatory:	  	  

		
	Address for Notice of Investing Entity or Person:	  	
		
	  
	  	
		
	  
	  	
		
	  
	  	
	
	Address for Delivery of Securities for Investing Entity or Person (if not same as above):
		
	  
	  	
		
	  
	  	
		
	  
	  	

 EIN Number: [PROVIDE THIS UNDER SEPARATE COVER]  
  
 [SIGNATURE PAGES CONTINUE] 
  

 30 








 [PURCHASER SIGNATURE PAGES TO CAMBRIDGE HEART SECURITIES 
 PURCHASE AGREEMENT] 
 IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. 
  

			
	Name of Investing Entity or Person:	  	 Saba Malak

		
	Signature of Authorized Signatory of Investing Entity or Person:	  	  

		
	Name of Authorized Signatory:	  	  

		
	Title of Authorized Signatory:	  	  

		
	Email Address of Authorized Signatory:	  	  

		
	Address for Notice of Investing Entity or Person:	  	
		
	  
	  	
		
	  
	  	
		
	  
	  	
	
	Address for Delivery of Securities for Investing Entity or Person (if not same as above):
		
	  
	  	
		
	  
	  	
		
	  
	  	

 EIN Number: [PROVIDE THIS UNDER SEPARATE COVER]  
  
 [SIGNATURE PAGES CONTINUE] 
  

 31 








 [PURCHASER SIGNATURE PAGES TO CAMBRIDGE HEART SECURITIES 
 PURCHASE AGREEMENT] 
 IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. 
  

			
	Name of Investing Entity or Person:	  	 Luis Martins

		
	Signature of Authorized Signatory of Investing Entity or Person:	  	  

		
	Name of Authorized Signatory:	  	  

		
	Title of Authorized Signatory:	  	  

		
	Email Address of Authorized Signatory:	  	  

		
	Address for Notice of Investing Entity or Person:	  	
		
	  
	  	
		
	  
	  	
		
	  
	  	
	
	Address for Delivery of Securities for Investing Entity or Person (if not same as above):
		
	  
	  	
		
	  
	  	
		
	  
	  	

 EIN Number: [PROVIDE THIS UNDER SEPARATE COVER]  
  
 [SIGNATURE PAGES CONTINUE] 
  

 32 








 [PURCHASER SIGNATURE PAGES TO CAMBRIDGE HEART SECURITIES 
 PURCHASE AGREEMENT] 
 IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. 
  

			
	Name of Investing Entity or Person:	  	 Roderick de Greef

		
	Signature of Authorized Signatory of Investing Entity or Person:	  	  

		
	Name of Authorized Signatory:	  	  

		
	Title of Authorized Signatory:	  	  

		
	Email Address of Authorized Signatory:	  	  

		
	Address for Notice of Investing Entity or Person:	  	
		
	  
	  	
		
	  
	  	
		
	  
	  	
	
	Address for Delivery of Securities for Investing Entity or Person (if not same as above):
		
	  
	  	
		
	  
	  	
		
	  
	  	

 EIN Number: [PROVIDE THIS UNDER SEPARATE COVER]  
  
 [SIGNATURE PAGES CONTINUE] 
  

 33 








 [PURCHASER SIGNATURE PAGES TO CAMBRIDGE HEART SECURITIES 
 PURCHASE AGREEMENT] 
 IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. 
  

			
	Name of Investing Entity or Person:	  	 Jeffrey Wiggins Trust

		
	Signature of Authorized Signatory of Investing Entity or Person:	  	  

		
	Name of Authorized Signatory:	  	  

		
	Title of Authorized Signatory:	  	  

		
	Email Address of Authorized Signatory:	  	  

		
	Address for Notice of Investing Entity or Person:	  	
		
	  
	  	
		
	  
	  	
		
	  
	  	
	
	Address for Delivery of Securities for Investing Entity or Person (if not same as above):
		
	  
	  	
		
	  
	  	
		
	  
	  	

 EIN Number: [PROVIDE THIS UNDER SEPARATE COVER]  
  
 [SIGNATURE PAGES CONTINUE] 
  

 34 








 [PURCHASER SIGNATURE PAGES TO CAMBRIDGE HEART SECURITIES 
 PURCHASE AGREEMENT] 
 IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. 
  

			
	Name of Investing Entity or Person:	  	 Richard Cohen

		
	Signature of Authorized Signatory of Investing Entity or Person:	  	  

		
	Name of Authorized Signatory:	  	  

		
	Title of Authorized Signatory:	  	  

		
	Email Address of Authorized Signatory:	  	  

		
	Address for Notice of Investing Entity or Person:	  	
		
	  
	  	
		
	  
	  	
		
	  
	  	
	
	Address for Delivery of Securities for Investing Entity or Person (if not same as above):
		
	  
	  	
		
	  
	  	
		
	  
	  	

 EIN Number: [PROVIDE THIS UNDER SEPARATE COVER]  
  
 [SIGNATURE PAGES CONTINUE] 
  

 35 








 [PURCHASER SIGNATURE PAGES TO CAMBRIDGE HEART SECURITIES 
 PURCHASE AGREEMENT] 
 IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. 
  

			
	Name of Investing Entity or Person:	  	 Bailard Emerging Life Sciences Fund I, L.P.

		
	Signature of Authorized Signatory of Investing Entity or Person:	  	  

		
	Name of Authorized Signatory:	  	  

		
	Title of Authorized Signatory:	  	  

		
	Email Address of Authorized Signatory:	  	  

		
	Address for Notice of Investing Entity or Person:	  	
		
	  
	  	
		
	  
	  	
		
	  
	  	
	
	Address for Delivery of Securities for Investing Entity or Person (if not same as above):
		
	  
	  	
		
	  
	  	
		
	  
	  	

 EIN Number: [PROVIDE THIS UNDER SEPARATE COVER]  
  
 [SIGNATURE PAGES CONTINUE] 
  

 36 








 [PURCHASER SIGNATURE PAGES TO CAMBRIDGE HEART SECURITIES 
 PURCHASE AGREEMENT] 
 IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. 
  

			
	Name of Investing Entity or Person:	  	 Osiris Investment LLC

		
	Signature of Authorized Signatory of Investing Entity or Person:	  	  

		
	Name of Authorized Signatory:	  	  

		
	Title of Authorized Signatory:	  	  

		
	Email Address of Authorized Signatory:	  	  

		
	Address for Notice of Investing Entity or Person:	  	
		
	  
	  	
		
	  
	  	
		
	  
	  	
	
	Address for Delivery of Securities for Investing Entity or Person (if not same as above):
		
	  
	  	
		
	  
	  	
		
	  
	  	

 EIN Number: [PROVIDE THIS UNDER SEPARATE COVER]  
  
 [SIGNATURE PAGES CONTINUE] 
  

 37 








 Cambridge Heart, Inc. 
 Schedule I 
  

												
	 Purchaser
	  	Subscription
Amount	  	Series D
Shares
Being
Purchased	  	Series D as
Converted
Being
Purchased	  	Aggregate
Short-Term
Warrants	  	Aggregate
Long-Term
Warrants
						
	 Cyril Malak
	  	$	50,000	  	50	  	609,756	  	304,878	  	182,927
						
	 John Hynes
	  	$	82,000	  	82	  	1,000,000	  	500,000	  	300,000
						
	 Vicente Madrigal
	  	$	300,000	  	300	  	3,658,537	  	1,829,269	  	1,097,561
						
	 Gerardo Madrigal
	  	$	50,000	  	50	  	609,756	  	304,878	  	182,927
						
	 Saba Malak
	  	$	300,000	  	300	  	3,658,537	  	1,829,269	  	1,097,561
						
	 Luis Martins
	  	$	315,000	  	315	  	3,841,463	  	1,920,732	  	1,152,439
						
	 Roderick de Greef
	  	$	50,000	  	50	  	609,756	  	304,878	  	182,927
						
	 Jeffrey Wiggins Trust
	  	$	300,000	  	300	  	3,658,537	  	1,829,269	  	1,097,561
						
	 Richard Cohen
	  	$	35,000	  	35	  	426,829	  	213,415	  	128,049
						
	 Bailard Emerging Life Sciences Fund I, L.P.
	  	$	100,000	  	100	  	1,219,512	  	609,756	  	365,854
						
	 Osiris Investment Partners, L.P.
	  	$	270,000	  	270	  	3,292,683	  	1,646,342	  	987,805
		  	 	 	  	 	  	 	  	 	  	 
	 Total
	  	$	1,852,000	  	1,852	  	22,585,366	  	11,292,686	  	6,775,611

  

 38